{"organizations": [], "uuid": "0022b08f356fac63840cb89d8c2fd9654847e7e2", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-icon-announces-deal-with-intel-all/brief-icon-announces-deal-with-intel-allowing-integration-of-the-intel-pharma-analytics-platform-for-clinical-trials-idUSFWN1RU0XC", "country": "US", "domain_rank": 408, "title": "BRIEF-ICON Announces Deal With Intel Allowing Integration Of The Intel Pharma Analytics Platform For Clinical Trials", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-17T17:05:00.000+03:00", "replies_count": 0, "uuid": "0022b08f356fac63840cb89d8c2fd9654847e7e2"}, "author": "", "url": "https://www.reuters.com/article/brief-icon-announces-deal-with-intel-all/brief-icon-announces-deal-with-intel-allowing-integration-of-the-intel-pharma-analytics-platform-for-clinical-trials-idUSFWN1RU0XC", "ord_in_thread": 0, "title": "BRIEF-ICON Announces Deal With Intel Allowing Integration Of The Intel Pharma Analytics Platform For Clinical Trials", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "intel pharma analytics", "sentiment": "negative"}, {"name": "intel", "sentiment": "negative"}, {"name": "intel pharma analytics platform for clinical trials reuters", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 17, 2018 / 2:08 PM / Updated 29 minutes ago BRIEF-ICON Announces Deal With Intel Allowing Integration Of The Intel Pharma Analytics Platform For Clinical Trials Reuters Staff 1 Min Read \nApril 17 (Reuters) - ICON PLC: \n* ICON ANNOUNCES AGREEMENT WITH INTEL ALLOWING INTEGRATION OF THE INTELÂ® PHARMA ANALYTICS PLATFORM FOR CLINICAL TRIALS \n* ICON PLC - AGREED ON PRELIMINARY DEAL TERMS WITH INTEL TO ENABLE ICON TO OFFER INTEL PHARMA ANALYTICS PLATFORM FOR USE IN CLINICAL TRIALS Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-04-17T17:05:00.000+03:00", "crawled": "2018-04-17T17:46:09.031+03:00", "highlightTitle": ""}